logo-loader
viewTissue Regenix Group PLC

Tissue Regenix CEO excited to soon be selling first products in UK

Steve Couldwell, chief executive of Tissue Regenix Group PLC (LON:TRX), caught up with Proactive's Andrew Scott following the appointment of Gareth Hywel Jones as their chief financial officer as well as the big news last month that they've been granted a Human Tissue Authority licence which will allow them to import and distribute their US-made products in the UK market.

The licence will initially be used to import CellRight’s BioRinse portfolio of bone healing products which are made at its Texas manufacturing facility.

They've also recently inked a non-exclusive three-year distribution agreement with Pennine Healthcare.

Pennine has an “established presence” in the UK orthopaedic market which should help to drive sales of Tissue’s bone and soft tissue products.

Quick facts: Tissue Regenix Group PLC

Price: 1.55 GBX

AIM:TRX
Market: AIM
Market Cap: £18.17 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix increasing throughput in its facility to meet 'exceptional...

Tissue Regenix PLC's (LON:TRX) Gareth Jones caught up with Proactive's Andrew Scott to update on developments in the regenerative medical devices maker's second half. ''The focus is really on increasing throughput in our San Antonia facility in the United States to allow us to meet the demand...

4 weeks, 1 day ago

2 min read